Senate Democrats React to Possible Abortion Pill Restrictions
Senate Democrats have expressed concerns over the Trump administration’s potential new restrictions on the abortion pill, mifepristone. This follows the Food and Drug Administration’s (FDA) independent evaluation of its safety and effectiveness.
In a letter sent to the FDA and the Department of Health and Human Services, Sen. Patty Murray (D-Wash.) and other members of the Senate Democratic Caucus urged officials not to rely on “junk science” for their reviews, particularly with findings that might support anti-abortion arguments.
The Democrats expressed their concern about what they perceive as an attempt to politicize the FDA’s assessments and regulations surrounding mifepristone.
The lawmakers took specific issue with a report from the Ethics and Public Policy Center (EPPC), a conservative think tank. It seems this report may influence the Trump administration’s stance on mifepristone.
They criticized the FDA for considering partisan reports in its reviews, calling it troubling. They pointed out that the administration appears eager to undermine established scientific findings if it serves its anti-abortion agenda.
The EPPC’s report claimed that nearly 11 percent of women experienced severe complications, such as sepsis or bleeding, within 45 days post-abortion with mifepristone, despite the fact that the drug, combined with misoprostol, has been deemed safe and effective since its FDA approval in 2000.
Under increasing pressure from Republicans and anti-abortion activists, the FDA is facing demands to reassess mifepristone without a thorough review, particularly in light of a recent approval of another generic medication. Activists are pushing for a return to the “in-person dispensing” requirement and other limitations.
In their letter, Democrats urged the administration to adhere to a recent court ruling that labeled current safety requirements regarding mifepristone as “irrational” and unfounded.
A federal court in Hawaii recently ruled that the existing Risk Evaluation and Mitigation Strategy (REMS) for mifepristone is unlawful, affirming the drug’s safety and effectiveness.
The lawmakers emphasized that as the FDA conducts its new review, it shouldn’t selectively use flawed reports to further its anti-abortion stance but should instead evaluate all available evidence that supports the drug’s safety and recognizes the challenges posed by existing regulations.
